The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to ...

Organon (OGN) announced completion of its acquisition of Dermavant Sciencesfrom Roivant (ROIV). Dermavant is a company dedicated to developing ...

VTAMA ® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Elsewhere, the Value Investor remains optimistic about Organon's earnings potential and sees the Dermavant acquisition as potentially accretive by 2026. An analysis by Myriam Alvarez also painted ...

Concurrent with the merger’s closure, Dermavant fulfilled its obligations ... Moreover, both Roivant Sciences Ltd. and Organon jointly released a press statement on October 28, 2024, formally ...

Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

“The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio. With the deal's closure, Organon has added Dermavant’s VTAMA (tapinarof ...